Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
|
|
- Kory Barber
- 5 years ago
- Views:
Transcription
1 Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1: Charite Universitatsmedizin Berlin, Berlin, Germany 2 Department of Infectious Disease, University of Brescia, Brescia, Italy *Corresponding author: thomas.berg@charite.de On-treatment predictors of response could be useful in optimizing treatment for patients with hepatitis C virus (HCV) genotype 2 or 3. Early virological response (EVR) has limited value as a predictor of response in genotype 2 or 3 patients, as it is achieved by 97% of this population. However, rapid virological response (RVR) measured at week 4 is a strong predictor of sustained virological response () in this group, and patients achieving an RVR may be suitable candidates for shorter treatment durations. Several small studies investigating the efficacy of shortened treatment durations in this population have been published; however, differences in study design have made their collective interpretation difficult. We discuss these studies, followed by a comparison of the data from ACCELERATE, the largest, randomized trial carried out to investigate abbreviated therapy in genotype 2 and 3 patients. The data confirm that RVR, and its use alongside significant baseline predictors, can assist in optimizing therapy. Patients achieving an RVR have high rates and might be candidates for shorter treatment duration, particularly those displaying a low viral load at baseline; however, the need to consider the increased rate of relapse versus the benefits of abbreviated therapy must also be considered. Conversely, in patients who do not achieve an RVR there is evidence to suggest they may benefit from intensified therapy (longer therapy and/or increased doses). As in genotype 1 and 4 patients, response-guided therapy aims to optimize treatment outcomes for individuals, without compromising rates. Introduction As Lee and Ferenci [1] discuss elsewhere in this supplement, it is no longer appropriate to generalize that patients with hepatitis C virus (HCV) genotype 1 and 4 are difficult to cure, because of viral kinetic evidence to the contrary. Conversely, it is no longer appropriate to think of all patients with HCV genotype 2 or 3 as easy to cure. Although genotype is an important driver of response and is useful in designing the initial treatment plan, it is clear that once treatment is initiated, rapid virological response (RVR) is the most important and powerful predictor of sustained virological response (). Indeed, available data show that, regardless of genotype, patients with an RVR have an approximately 9% chance of achieving an after 24 weeks of treatment with pegylated interferon-α2a (PEG-IFN-α2a) plus ribavirin [2,3]. Early virological response (EVR) is of limited value in the management of patients with HCV genotype 2 or 3 infection. EVR is defined as undetectable HCV RNA (<5 IU/ml) in serum or 2 log 1 drop in HCV RNA over baseline after 12 weeks of treatment. Virtually all patients (97%) randomized to 24 weeks of treatment with PEG-IFN-α2a plus ribavirin in the large, international ACCELERATE trial achieved an EVR [4]. In genotype 2 and 3 patients, response-guided therapy using measurement of the virological response after 4 weeks of combination therapy allows the treatment regimen to be tailored to the individual. Abbreviated therapy for patients infected with HCV genotype 2 and 3 Treatment guidelines recommend that patients infected with HCV genotype 2 or 3 infection be treated for 24 weeks with a combination of PEG-IFN-α2a plus ribavirin 8 mg/day [5,6]. This recommendation is based on the outcome of a large, randomized, international trial, in which patients were randomized to treatment for 24 or 48 weeks with PEG-IFN-α2a 8 International Medical Press
2 T Berg & G Carosi (4 kda) (Pegasys ; Roche, Basel, Switzerland) plus ribavirin (Copegus ; Roche) at a dose of either 8 mg/day or a weight-based 1,/1, mg/day [7]. rates ranged from 79 84% across the four treatment groups in this trial, with no significant differences between any combination of treatment duration and ribavirin dose [7]. The finding that maximal rates could be obtained with 24 weeks of treatment has spurred researchers to investigate even shorter durations of treatment for patients infected with HCV genotypes 2 or 3. Abbreviated regimens would be less expensive and more convenient, and might have tolerability advantages over the standard 24-week regimen. To date, five trials have examined abbreviated week treatment regimens for genotype 2 and 3 [3,8 11]. The various trials differ greatly in study design; thus, great care is necessary when examining the results, especially when attempting to compare results of studies or generalize the findings to a broad population. An overview of the study design features of the five trials is presented in Table 1. The duration of treatment in the abbreviated regimen varied across trials from weeks, but it was how patients were assigned to abbreviated treatment that had the greatest effect on the final rates. In three of the trials, treatment duration was determined on the basis of RVR status at week 4 [8 1]. In contrast, the other two studies randomized patients at baseline to abbreviated treatment or the standard 24-week duration [3,11]. Given what is known about the influence of RVR on rates, it is clear that studies which pre-selected patients with an RVR for abbreviated treatment would produce higher rates than those that did not pre-select patients with favourable characteristics. This is exactly what has been reported. A shorter treatment duration for those who are fast to respond The merits of abbreviated therapy can be explored by thorough consideration of the results of two studies: one that assigned patients to abbreviated therapy on the basis of RVR status [9], and a second, larger trial (ACCELERATE) that randomized patients at baseline to an abbreviated regimen or the standard duration of therapy [3]. Mangia et al. [9] randomized 283 patients with HCV genotype 2 or 3 to a standard 24-week regimen or a variable treatment duration (12 or 24 weeks) with PEG-IFN-α2b (12 kda; PegIntron ; Schering-Plough Corporation, Kenilworth, NJ, USA) 1. μg/kg/week plus ribavirin 1, or 1, mg/day. Patients randomized to the variable regimen were assigned at week 4 on the basis of their RVR status to complete a total of either 12 or 24 weeks of treatment. As might be expected, the highest rate in the variable duration group was obtained in patients with an RVR who were assigned to 12 weeks of treatment (85% versus 64% in those patients without an RVR treated for 24 weeks; Figure 1). The overall rate in the group randomized at baseline to 24 weeks of treatment was 76% [9]. When overall rates are computed for the two groups, there is seemingly little difference between them: 76% of patients randomized to the standard 24-week duration of treatment and 77% in those randomized to the variable regimen with treatment duration based on RVR. On this basis, the variable duration strategy appears to be a reasonable alternative to the standard 24-week regimen; however, a more careful inspection of the data reveals a potential drawback of abbreviated therapy genotype 2 or 3 Table 1. Summary of studies that have investigated abbreviated treatment for HCV genotype 2 or 3 infection Treatment Assignment to Definition of RVR, Patients HCV duration, abbreviated RBV dose, serum HCV RNA Study treated, n genotype weeks regimen Treatment mg/day level, IU/ml Randomized trials Shiffman et al. [3] 1,463 2, 3 16 versus 24 Baseline PEG-IFN-α2a 8 <5 18 µg/week + RBV Yu et al. [11] versus 24 Baseline PEG-IFN-α2a 1,/1, <5 18 µg/week + RBV von-wagner et al. [1] 153 2, 3 16 versus 24 Week 4 PEG-IFN-α2a 8 1, <6 18 µg/week + RBV Mangia et al. [9] 283 2, 3 12 versus 24 Week 4 PEG-IFN-α2b 1,/1, <5 1. µg/kg/week + RBV Non-randomized trial Dalgard et al. [8] 122 2, 3 14 versus 24 Week 14 PEG-IFN-α2b 8 1,4 <5 1.5 µg/kg/week + RBV HCV, heptitis C virus; PEG-IFN-α2a, pegylated interferon-α2a; PEG-IFN-α2b, pegylated interferon-α2b; RBV, ribavirin; RVR, rapid virological response International Medical Press
3 Optimizing outcomes in genotype 2 and 3 patients patients treated with abbreviated regimens are more likely to experience virological relapse compared with those treated for the standard duration. When only patients with an RVR are considered, the relapse rate was considerably lower in patients randomized to 24 weeks of treatment (2%) than in patients assigned to 12 weeks in the variable duration group (11%; Figure 1) [9]. More patients randomized to the 24-week group withdrew from treatment than in the abbreviated treatment group. Thus, the higher relapse rates in the abbreviated treatment group and the higher dropout rates in the standard group tend to cancel each other out and create the appearance that outcomes are similar in both strategies. The largest trial to examine the merits of abbreviated therapy in patients with HCV genotype 2 or 3 infection was ACCELERATE, which randomized 1,469 patients Figure 1. Rates of virological response and relapse in patients treated with PEG-IFN-α2b in a randomized trial A Patients, % B Patients, % %91% EOTR 52% 48% 95% 85% 68% 64% RVR No RVR RVR No RVR (n=45) (n=25) 12 weeks 24 weeks (n=133) (n=8) 24 Weeks Variable duration* 2% 8% 11% 6% RVR No RVR RVR No RVR (n=45) (n=25) 12 weeks 24 weeks (n=133) (n=8) 24 Weeks Variable duration* Rates of (A) virological response and (B) relapse in patients treated with pegylated interferon-α2b 1. μg/kg/week plus ribavirin 1, or 1, mg/day in a randomized trial by Mangia et al. [9]. *Treatment duration was determined on the basis of rapid virological response (RVR; HCV RNA <5 IU/ml at week 4). EOTR, end of treatment response;, sustained virological response. at baseline to either 16 or 24 weeks of treatment with PEG-IFN-α2a 18 μg/week plus ribavirin 8 mg/day [3]. Patients with major protocol deviations or <8% exposure to medication were excluded from the protocol-planned primary analysis. In this standard analysis, the rate in patients randomized to 24 weeks of treatment was significantly greater than in those randomized to 16 weeks of treatment (76% versus 65%; odds ratio.59, 95% confidence interval.46.76; P<.1). The results of an intent-to-treat analysis were consistent with the pre-specified analysis: rates were 7% versus 62% for 24 weeks versus 16 weeks, respectively (odds ratio.67, 95% confidence interval.54.84; P<.1) [3]. These findings were obtained despite a higher rate of withdrawal in patients randomized to 24 weeks compared with 16 weeks of treatment. What do the results of ACCELERATE tell us about the management of HCV genotype 2 or 3 infection? The findings demonstrate conclusively that it is not appropriate to recommend abbreviated treatment as a general strategy for patients with genotype 2 or 3 infection [3]. On the surface, this seems to contradict the findings of the trial by Mangia et al. [9]. However, closer inspection of data from ACCELERATE confirms that RVR is a powerful predictor of outcomes in patients with HCV genotype 2 or 3, and also sheds light on the appropriateness of assigning patients to abbreviated treatment based on their RVR status [3]. Two thirds (67%) of all treated patients achieved an RVR in ACCELERATE. Consistent with the overall results of the trial, the rate in patients with an RVR who were treated for 24 weeks was higher (9%) than in patients treated for 16 weeks (82%; Figure 2). The rates were considerably lower in patients without an RVR (49% in patients treated for 24 weeks versus 27% in patients treated for 16 weeks). When baseline HCV RNA levels are superimposed on RVR, it is apparent that these two factors exert a powerful influence on rates. Although, as shown in Figure 2, treatment for 24 weeks produces consistently higher rates than an abbreviated 16-week regimen, regardless of baseline HCV RNA levels. In patients with low HCV RNA levels, defined as 4, IU/ml, the rate was 95% in those treated for 24 weeks and 9% in those treated for 16 weeks in ACCELERATE (Figure 3). In contrast, rates were 88% in patients with a baseline HCV RNA level of >8, IU/ml who were treated for 24 weeks and 78% in patients treated for 16 weeks. It is also clear that the absolute difference in rates between patients with high and low baseline HCV RNA levels is greater in patients randomized to abbreviated therapy (12% versus 7% in those randomized to 24 weeks). Antiviral Therapy 13 Suppl 1 19
4 T Berg & G Carosi Figure 2. Sustained virological response rates in patients with and without a rapid virological response Figure 3. Sustained virological response rates in patients with a rapid virological response All patients (n=1,291) RVR: yes 67% (871/1,291) RVR: no 33% (4/1,291) 16 Weeks 24 Weeks 1% 8% 6% 4% % 82 9 % 378/461 37/41, % % 95% n=123 n=11 4, 84% 92% n=43 n=49 4, 8, 16 Weeks 24 Weeks 78% 88% n=295 n=26 >8, 1% 16 Weeks 24 Weeks 8% 6% 4% % % 55/5 15/215 Pretreatment serum HCV RNA, IU/ml Sustained virological response () rates in patients with and without a rapid virological response (RVR; HCV RNA <5 IU/ml at week 4) treated with peginterferon-α2a (PEG-IFN-α2a) 18 μg/week plus ribavirin 8 mg/day by treatment duration in ACCELERATE [4]. Sustained virological response () rates in patients with a rapid virological response (RVR; HCV RNA <5 IU/ml at week 4) treated with peginterferon-α2a 18 μg/week plus ribavirin 8 mg/day by treatment duration and baseline serum HCV RNA level in ACCELERATE [4]. As stated above, most genotype 2 or 3 patients achieve an EVR. An interesting trend is observed when outcomes are compared in patients based on the time at which an individual becomes HCV RNA negative. Among patients who become HCV RNA negative by week 4 (RVR) or by week 12 (complete EVR), the end of treatment (EOT) virological response rate was almost identical (95% and 94%, respectively). However, relapse is unusual in patients with an RVR and is more common in those who do not become HCV RNA negative until week 12. Thus, rates in these groups are divergent: 9% in those with an RVR and 57% in those with a complete EVR. This is reminiscent of what is observed in patients infected with HCV genotype 1 (see article by Lee and Ferenci in this supplement [1]). Genotype 1 patients with a partial EVR have much lower rates (27%) than patients who have an RVR (87%) or a complete EVR (68%) because of higher relapse rates during follow-up. Differences between HCV genotypes 2 and 3 There were differences in the virological response rates between patients infected with genotypes 2 and 3 in ACCELERATE [3]. Among patients treated for 24 weeks in the intent-to-treat population, those infected with HCV genotype 2 had a higher RVR rate (69% versus 59%), EVR rate (94% versus 85%), EOT response rate (84% versus 8%) and rate (75% versus 66%) as compared with patients infected with HCV genotype 3. The trend was similar in patients randomized to 16 weeks of treatment, although the rate was identical in patients with genotype 2 and 3 (62%). Among patients with an RVR, the rates were identical in patients with genotype 2 and 3 randomized to 24 weeks of treatment (85%) and similar in those randomized to 16 weeks of treatment (78% in genotype 2 versus 8% in genotype 3). The greatest difference between genotypes was among patients without an RVR who were randomized to 24 weeks of treatment: the rate was 53% in those with genotype 2 and 39% in those with genotype 3 [3]. Mangia et al. [9] also observed differences in the rate between patients infected with genotype 2 and 3. The overall rate was 8% in patients infected with genotype 2 and 66% in patients infected with genotype 3 (P<.1). As the rate was identical (76%) in genotype 2 and 3 patients randomized to the standard 24-week regimen, this difference was driven entirely by the difference in rates in patients randomized to the variable duration regimen (82% in genotype 2 versus 62% in genotype 3). High baseline HCV RNA levels have a marked effect on rates in patients infected with genotype 3. This trend has been observed in several trials that have examined abbreviated therapy and is particularly evident in patients treated with abbreviated regimens [3,8,1]. 8 International Medical Press
5 Optimizing outcomes in genotype 2 and 3 patients The effect of ribavirin dose An issue of interest is whether ribavirin dose increases rates in patients receiving abbreviated regimens (the issue of ribavirin dose in the era of responseguided therapy will be discussed in greater detail by Dusheiko et al. [12] in a subsequent article in this supplement). The recommended dose of ribavirin in genotype 2 or 3 patients is a fixed dose of 8 mg/day, which was decided on the basis of the results of a large pivotal trial by Hadziyannis et al. [7]. There was no significant difference in rates in HCV genotype 2 or 3 patients treated for 24 weeks (or 48 weeks) with 8 mg/day or 1,/1, mg/day ribavirin. This indicates that the dose of ribavirin is less important in patients infected with HCV genotypes 2 or 3 than genotypes 1 or 4. It might even be possible to reduce the dose further in patients receiving the standard 24-week regimen [13]. Several trials of abbreviated therapy have used higher doses of ribavirin (8 1,4 mg/day) [8 11], but the use of a higher dose of ribavirin in these trials was empirical. The lack of a control group with a different dose of ribavirin in these trials makes it impossible to tell if the higher dose actually improved outcomes. Although ACCELERATE used a fixed 8 mg/day dose of ribavirin, the results could shed light on the importance of ribavirin dose with abbreviated regimens. There was a benefit from higher ribavirin exposure in both patients with and without an RVR when they received <17 doses PEG-IFN-α2a. However, when the number of PEG-IFN-α2a doses was >17, ribavirin exposure did not significantly contribute to in patients with or without an RVR [14]. Further study is needed to confirm the optimal ribavirin dose in genotype 2 or 3 patients receiving a shorter treatment duration. Extending treatment duration in those who are slow to respond There are data from randomized prospective trials which show that prolonging the duration of treatment increases rates in genotype 1 patients who are slow responders [15,16] (see the article by Ferenci and Lee [1] in this supplement). This raises the question of whether intensification of treatment could increase rates in genotype 2 or 3 patients who do not achieve an RVR. No data from prospective trials are available on this topic; however, this question has been addressed through a retrospective analysis of data [17] from the trial by Hadziyannis et al. [7]. rates ranged from 65 76% across the four treatment groups in this trial (Figure 4). Consistent with results observed in genotype 1 patients, relapse rates decreased in inverse proportion to the intensity of treatment, and were lowest in those treated for 48 weeks with PEG- IFN-α2a plus ribavirin 1,/1, mg/day (4%) and highest in those treated for 24 weeks with PEG-IFNα2a plus ribavirin 8 mg/day (26%) [17]. Although these results must be confirmed in a prospective study, they suggest that intensification of therapy may be effective in increasing rates in genotype 2 or 3 patients who do not achieve an RVR at week 4. Conclusion In conclusion, available data from ACCELERATE and smaller studies demonstrate that genotype 2 or 3 patients with an RVR can achieve high rates with abbreviated therapy. There is a trade off between slightly higher relapse rates in patients treated with abbreviated regimens and slightly higher withdrawal rates in those treated for the standard duration. A higher ribavirin dose in patients who receive a shorter duration might reduce relapse, but this requires further study, as does the strategy of extending the treatment duration to 48 weeks in patients without an RVR at week 4. The highest rates and lowest relapse rates are obtained in patients with an RVR who have low baseline HCV RNA levels ( 4, IU/ml). The PROPHESYS cohort may provide Figure 4. Rate of sustained virological response and relapse in patients without a rapid virological response treated with PEG-IFN-α2a plus ribavirin for 24 or 48 weeks in a large, randomized, international trial Patients, % n= Weeks, 8 mg/day 24 Weeks, 1,/1, mg/day 48 Weeks, 8 mg/day 48 Weeks, 1,/1, mg/day Relapse Rate of sustained virological response () and relapse in patients without a rapid virological response (HCV RNA <5 IU/ml at week 4) treated with peginterferon-α2a (PEG-IFN-α2a) 18 μg/week plus ribavirin 8 mg/day or 1,/1, mg/day for 24 or 48 weeks in a large, randomized, international trial [17]. Antiviral Therapy 13 Suppl 1 21
6 T Berg & G Carosi further insight into the potential for response-guided therapy in this population. Acknowledgements We thank Health Interactions Ltd., UK who provided editorial support on behalf of Roche. Disclosure statement TB has served as consultant and acted as scientific advisor to Hoffmann-La Roche and received grants from Hoffmann-La Roche as part of participation within clinical trials. GC is an investigator, speaker and expert for Hoffmann-La Roche, Gilead, Bristol-Myers Squibb and Vertex pharmaceutical companies. He receives no salary and no regular remuneration or royalty from any drug company, and owns no stock option from any drug company. References 1. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 8; 13 Suppl 1: Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (4 kd)/ribavirin therapy. Hepatology 6; 43: Shiffman ML, Suter FS, Bacon BR, et al. Peginterferon alpha-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 7; 357: Shiffman M, Pappas S, Bacon B, et al. Utility of virological response at weeks 4 and 12 in the prediction of rates in genotype 2/3 patients treated with peginterferon alpha-2a plus ribavirin: findings from ACCELERATE. Hepatology 6; 44 Suppl 1:316A 317A. 5. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 6; 13: Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 4; 39: Hadziyannis S, Sette H, Morgan T, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 4; 14: Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 4; 4: Mangia A, Santoro R, Minerva N, et al. Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 5; 352: von-wagner M, Huber M, Berg T, et al. Peginterferon alpha-2a and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 5; 129: Yu ML, Dai CY, Huang JF, et al. A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 7; 56: Dusheiko G, Nelson D, Reddy KR. Ribavirin considerations in treatment optimization. Antivir Ther 8; 13 Suppl 1: Ferenci P, Brunner H, Laferl H, et al. Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (Pegasys) plus ribavirin (Copegus): interim results of a randomized controlled trial. J Hepatol 6; 44 Suppl 2:S Shiffman M, Pappas S, Greenbloom S, et al. Effect of drug exposure on sustained virological response () in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alpha-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks. Hepatology 6; 44 Suppl 1:317A. 15. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alpha-2a plus ribavirin. Gastroenterology 6; 13: Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 6; 131: Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J Hepatol 7; 46 Suppl 1:S6. Accepted for publication November International Medical Press
Therapy of Hepatitis C. Adrian M. Di Bisceglie
Session V Therapy of Hepatitis C Adrian M. Di Bisceglie Saint Louis University Liver Center, St. Louis, Mo. Tremendous progress has been made in developing effective therapies for hepatitis C. The process
More informationThe time factor in the management of chronic hepatitis C
11-8/8//4/2-235 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 8 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol.. N. 4, pp. 2-235, 8 POINT OF VIEW The time factor in the management of chronic
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationPersonalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2
Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationWhich patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the accordion regimen? q
Journal of Hepatology 47 (2007) 580 587 Special article Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the accordion regimen? q Patrick Marcellin 1, *, E.
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationAssessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.3.203 Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C Jung Hyun Kwon
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationInterferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives
TAJ December 2008; Volume 21 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review Article Interferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives
More informationAin Shams University. The Egyptian Journal of Medical Human Genetics.
The Egyptian Journal of Medical Human Genetics (2012) 13, 331 335 Ain Shams University The Egyptian Journal of Medical Human Genetics www.ejmhg.eg.net www.sciencedirect.com ORIGINAL ARTICLE Virologic response
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationProspective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron
Prospective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron David Finkelman, MD, MBA Janet McRea, LPN Reprint requests to: David
More informationOptimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
Journal of Viral Hepatitis, 2012, 19, 766 774 doi:1111/j.1365-2893.2012.01624.x Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
More informationTreatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy
ORIGINAL ARTICLE September-October, Vol. 13 No. 5, 2014: 503-509 Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy Ajit Sood, Vandana
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationOriginal article The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype
Antiviral Therapy 14:577 584 Original article The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype Alessio Aghemo 1, Maria
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationPegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.08 Subsection: Anti-infective Agents Original Policy Date: January 1, 2006 Subject: Pegasys Ribavirin
More informationAnemia as a predictor of response to antiviral therapy in chronic hepatitis C
DOI: 10.4149/BLL_2013_044 Bratisl Lek Listy 2013; 114 (4) CLINICAL STUDY Anemia as a predictor of response to antiviral therapy in chronic hepatitis C Urbanek P 1, Kreidlova M 2, Dusek L, 3 Bruha R 4,
More informationOver the past decade, the introduction of
MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS: CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α PLUS RIBAVIRIN Raymond T. Chung, MD* ABSTRACT Coinfection with hepatitis C virus (HCV) is common
More informationInfergen Monotherapy. Infergen (interferon alfacon-1) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.03 Subject: Infergen Monotherapy Page: 1 of 7 Last Review Date: March 13, 2014 Infergen Monotherapy
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationConventional Interferon Alfa-2b and Ribavirin for 12 Versus 24 Weeks in HCV Genotype 2 or 3
ORIGINAL ARTICLE Conventional Interferon Alfa-2b and Ribavirin for 12 Versus 24 Weeks in HCV Genotype 2 or 3 Javed Iqbal Farooqi and Rukhsana Javed Farooqi* ABSTRACT Objective: To determine the efficacy
More informationThe combination of pegylated interferon (peginterferon)
GASTROENTEROLOGY 2008;135:451 458 BILIARY TRACT Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response PETER FERENCI,* HERMANN LAFERL, THOMAS
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationTechnology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 NICE 2018. All rights reserved. Subject to
More informationU.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for Difficult-to-Treat HCV Genotype 1 Patients
Dig Dis Sci (2011) 56:880 888 DOI 10.1007/s10620-010-1504-y ORIGINAL ARTICLE U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for Difficult-to-Treat HCV Genotype 1 Patients
More informationPeginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
original article Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3 Alessandra Mangia, M.D., Rosanna Santoro, Bs.D., Nicola Minerva, M.D., Giovanni L. Ricci, M.D., Vito Carretta,
More informationThe medical management of hepatitis C
CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS INFECTED WITH HIV: THE APRICOT STUDY Douglas T. Dieterich, MD* ABSTRACT Currently,
More information1. SYNOPSIS. AWB-ML21645 Date: April 20, 2016 Title of the observational study
1. SYNOPSIS AWB-ML21645 Date: April 20, 2016 Title of the observational study INVESTIGATORS SPONSOR Noninterventional study on the quality assurance of the therapy of chronic hepatitis C with Peg-(40kd)-Interferon
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Long-term Pegylated Interferon Monotherapy Following 72 Weeks of Pegylated Interferon and Ribavirin in Hepatitis C Virus Genotype-1-infected Slow Responders Shinya Watanabe 1, Yoshimasa
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationOver the last 2 years exciting novel pharmacogenetic
Clinical Utility of Interleukin-28B Testing in Patients With Genotype 1 Michelle Lai and Nezam H. Afdhal See Editorial on Page 5 Over the last 2 years exciting novel pharmacogenetic data have emerged on
More informationInterferon free therapy Are we getting there? Graham R Foster Queen Marys University of London
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationJournal of Engineering Technology Volume 1, Jan. 2013, Pages 1-9. Prolongation and its Fusion Treatment for HCV-4 Disease
rolongation and its Fusion Treatment for HCV-4 Disease El Shazly 1 and Salwa Hadad 2 1 Internal medicine1 and pathology 2 Departments, Ain Shams University, Cairo, Egypt Abstract: The recommended treatment
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationPeginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV or 3 Mitchell L. Shiffman, M.D., Fredy Suter, M.D., Bruce R. Bacon,
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationExpert opinion on the treatment of patients with chronic hepatitis C
Journal of Viral Hepatitis, 2009, 16, 75 90 doi:10.1111/j.1365-2893.2008.01012.x REVIEW Expert opinion on the treatment of patients with chronic hepatitis C S. Zeuzem, 1 T. Berg, 2 B. Moeller, 3 H. Hinrichsen,
More informationChronic infection with hepatitis C virus (HCV)
VIRAL HEPATITIS Concordance of Sustained Virological Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir- Containing Regimens for Hepatitis C Virus Eric M. Yoshida, 1 Mark S. Sulkowski, 2 Edward
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationEfficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon Ribavirin in daily practice
46 Ridruejo E, et al., 2010; 9 (1): 46-51 ORIGINAL ARTICLE January-March, Vol. 9 No.1, 2010: 46-51 Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationPeginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106
Issue date: September 2010 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Part review of NICE technology appraisal guidance 75 and 106 National Institute for Health and Clinical
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationCLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2010;138:108 115 Randomized Study of Peginterferon- 2a Plus Ribavirin vs Peginterferon- 2b Plus Ribavirin in Chronic Hepatitis C MARIA GRAZIA RUMI,* ALESSIO AGHEMO,* GIAN MARIA PRATI,*
More informationReview Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection
Antiviral Therapy 211; 16:1187 121 (doi: 1.3851/IMP1934) Review Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection Peter Ferenci 1 *, K Rajender Reddy 2 1 Department
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationTreatment guidance for Chronic Hepatitis C Infection
Treatment guidance for Chronic Hepatitis C Infection A meeting of the network was held on 11 April 2008 at which the current evidence base for hepatitis C was reviewed. These guidelines have been produced
More informationTreatment of chronic hepatitis C virus infection in the near future
EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the
More informationPeginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection
GASTROENTEROLOGY 2010;138:116 122 Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection ANTONIO ASCIONE,* MASSIMO
More informationPretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy
Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Teerha Piratvisuth MD. Prince of Songkla University Treatment of chronic hepatitis C and response rates
More informationCHRONIC HCV TREATMENT: In Special Populations.
CHRONIC HCV TREATMENT: In Special Populations. By Taher EL-ZANATY Prof. of Internal Medicine CAIRO UNIVERSITY Introduction: HCV is the major cause of chronic hepatitis in Egypt. Its end stage is liver
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationCurrent Standards in the Treatment of Chronic Hepatitis C
REVIEW ARTICLE Current Standards in the Treatment of Chronic Hepatitis C Wolf Peter Hofmann, Christoph Sarrazin, Stefan Zeuzem SUMMARY Background: In Germany, 0 000 to 500 000 people are chronically infected
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationOptimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:610 615 Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection YOAV LURIE,* REGINE ROUZIER PANIS, GEORGE
More informationMulticenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population
Jin et al. BMC Gastroenterology 2013, 13:74 RESEARCH ARTICLE Open Access Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population Young-Joo Jin 1,
More informationfrom 29 March 2012 Effect estimates [95% CI] Telaprevir + PegIFN/RBV vs. PegIFN/RBV
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationPeginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response
GASTROENTEROLOGY 2010;138:503 512 Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response PETER FERENCI,*,## HERMANN LAFERL, THOMAS MATTHIAS
More informationAntiviral Therapy 13:
Antiviral Therapy 13:1047 1055 Original article Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV HIV-coinfected patients Cristina
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationTreatment of Chronic Hepatitis C in Non-Responders
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Chronic Hepatitis C in Non-Responders Jay H. Hoofnagle INTRODUCTION The treatment of chronic hepatitis C has evolved markedly over
More informationRibavirin (Medicare Prior Authorization)
Prior Authorization Form ARKANSAS BLUE CROSS AND BLUE SHIELD Medi-Pak Rx (PDP), Medi-Pak Advantage (PFFS), and Medi-Pak Advantage PPO Ribavirin (Medicare Prior Authorization) This fax machine is located
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationSafety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
Journal of Viral Hepatitis, 2007, 14, 788 796 doi:10.1111/j.1365-2893.2007.00871.x Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice:
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationGeneral Statement for Drugs for the Treatment of Hepatitis C
General Statement for Drugs for the Treatment of Hepatitis C Use the following criteria to determine patient eligibility for subsidisation under the PBS for hepatitis C treating agents. By writing a PBS
More information2016: The State of HIV & Hepatitis C in the District
2016: The State of HIV & Hepatitis C in the District Travis A. Gayles, MD, PhD Chief Medical Officer, HIV/AIDS, Hepatitis, STD, and TB Administration Division Chief, STD and TB Control February 29, 2016
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of
More informationAnnals of Hepatology 2003; 2(3): July-September: Original Article
Annals of Hepatology 2003; 2(3): July-September: 135-139 Annals of Hepatology Original Article Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican
More informationLaboratory and Clinical Diagnosis of HCV Infection
Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 VIRAFERONPEG 50 µg/ 0.5 ml powder and solvent for injectable solution Pack of 1 (CIP: 355 189.3)
More informationIntravenous drug use is currently the main transmission
A Prospective Controlled Study of Interferon-Based Therapy of Chronic Hepatitis C in Patients on Methadone Maintenance Stefan Mauss, 1 Florian Berger, 1 Joerg Goelz, 2 Bernhard Jacob, 3 and Günther Schmutz
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More information